Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.57x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HAE stock price at discount vs MRVL $102.84 current versus $150.52 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRVL's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · MRVL FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.57x
Capital structure 98% equity / 2% debt · EV / Revenue 24.41x · EV / EBITDA 45.12x
MRVL carries the larger enterprise value at $199.99B against $5.68B; HAE trades on the lower EV / Revenue multiple (4.26x vs 24.41x); HAE on the lower EV / EBITDA (21.57x vs 45.12x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
MARVELL TECHNOLOGY, INC · implied price per share
Bear
$20.57
Base
$25.11
Bull
$31.24
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.56x
0.35x
Net debt / EBITDA
Leverage against operating earnings
3.80x
0.53x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$2.64B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$1.24B
$4.97B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.